SCHEMBL16570797

SCHEMBL16570797

O=S(=O)(c1cccc2cccnc12)n1cc(F)c2cnc(Nc3ccc(N4CCNCC4)cc3)nc21

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
WEE1 P30291 3/20 0.54
PLK1 P53350 2/20 0.54
CDK4 P11802 11/20 0.49
CDK6 Q00534 4/20 0.49
JAK2 O60674 4/20 0.46
BRD4 O60885 4/20 0.46
CCND3 P30281 6/20 0.46
CCND1 P24385 5/20 0.46
CCND2 P30279 4/20 0.46
JAK1 P23458 2/20 0.45
BRD2 P25440 2/20 0.45
JAK3 P52333 2/20 0.45
BRD3 Q15059 2/20 0.45
BRDT Q58F21 2/20 0.45
CCNA2 P20248 2/20 0.44
CDK2 P24941 2/20 0.44
NUAK1 O60285 1/20 0.44
FGFR1 P11362 1/20 0.44
FGFR2 P21802 1/20 0.44
FGFR4 P22455 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16570158 0.90 CDK4 (0.52) WEE1PLK1CDK4CDK6JAK2
SCHEMBL16570589 0.85 FGFR4 (0.59) JAK2BRD4JAK1BRD2JAK3
SCHEMBL16580906 0.84 WEE1 (0.53) WEE1PLK1CDK4CDK6JAK2
SCHEMBL16570263 0.82 JAK2 (0.49) CDK4CDK6JAK2BRD4CCND3
SCHEMBL16570214 0.78 FGFR4 (0.51) WEE1PLK1CDK4JAK2BRD4
SCHEMBL16570146 0.78 JAK2 (0.58) WEE1CDK4CDK6JAK2BRD4
SCHEMBL16570240 0.76 MARK3 (0.47) CDK4CDK6JAK2BRD4CCND1
SCHEMBL16570775 0.76 GFER (0.44) WEE1CDK4CDK6JAK2BRD4
SCHEMBL16570942 0.76 FGFR4 (0.63) CDK4JAK2BRD4FGFR4
SCHEMBL16580851 0.75 FGFR4 (0.57) JAK2BRD4JAK1BRD2JAK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160222014-A1 COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS ASANA BIOSCIENCES, LLC (US) 2016-08-04 US claimed
WO-2015038417-A1 COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS ASANA BIOSCIENCES, LLC (US) 2015-03-19 WO claimed
US-20160222014-A1 COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS ASANA BIOSCIENCES, LLC (US) 2016-08-04 US disclosed
WO-2015038417-A1 COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS ASANA BIOSCIENCES, LLC (US) 2015-03-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160222014-A1 COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS SRC, PTK2, FYN WEE1 1512/4885PLK1 357/4885CDK4 243/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.